Hvilken er prisen på Marinus Pharmaceuticals, Inc. (MRNS)

Prisen på Marinus Pharmaceuticals, Inc. (MRNS) er $0.55

Hva er markedsverdien på Marinus Pharmaceuticals, Inc. (MRNS)

Markedsverdien på Marinus Pharmaceuticals, Inc. (MRNS) er $28.90M

Marinus Pharmaceuticals, Inc. (MRNS) Utestående Aksjer

Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.

År	Utestående aksjer	Endre
2026 (TTM)	57.23M	6.48%
2023	53.75M	37.56%
2022	39.07M	6.47%
2021	36.70M	34.57%
2020	27.27M	100.10%
2019	13.63M	33.30%
2018	10.22M	73.72%
2017	5.89M	20.73%
2016	4.87M	30.69%
2015	3.73M	142.49%
2014	1.54M	-23.70%
2013	2.02M	0.00%
2012	2.02M	0.00%

År

Utestående aksjer

Endre

2026 (TTM)

57.23M

6.48%

2023

53.75M

37.56%

2022

39.07M

6.47%

2021

36.70M

34.57%

2020

27.27M

100.10%

2019

13.63M

33.30%

2018

10.22M

73.72%

2017

5.89M

20.73%

2016

4.87M

30.69%

2015

3.73M

142.49%

2014

1.54M

-23.70%

2013

2.02M

0.00%

2012

2.02M

0.00%

Selskap	Utestående aksjer	Forskjell	Land
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	343.65%	US
Moderna, Inc. MRNA.US	396.00M	591.95%	US
Argenx SE ARGX.US	62.19M	8.66%	NL
CSL Limited CSL.AX	483.58M	744.98%	AU
Lonza Group AG LONN.SW	-	-	CH

Selskap

Utestående aksjer

Forskjell

Land